Latest filingAug 20, 2026Most recent Form 4
KROS
Keros Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$10.1M4 sells
Net open-market-$10.1M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period4transactions
- S · Open-market sells · dominant4 · 100%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- CLO · dominant1 · 20%
- CSO1 · 20%
- CTRL1 · 20%
- Director1 · 20%
- VP1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (4)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeNewton Charles W.Common Stock · Direct
12,114Aug 18, 2026
Cho EstherCommon Stock · Direct
35,770Aug 18, 2026
Lerner Lorena RaquelCommon Stock · Direct
27,559Aug 18, 2026
Tanini AnnitaCommon Stock · Direct
45,144Aug 18, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- CE-$46.2k
- LR-$36.7k
- TA-$12.6k
- NW-$5.7k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
KROS transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| KROS | Tanini Annita | CTRLVP | sale | 1.22k | -$1.25M | S | +1.1% | 08/20 | 08/18 | |
| KROS | Lerner Lorena Raquel | CSO | sale | 3.56k | -$3.67M | S | +1.1% | 08/20 | 08/18 | |
| KROS | Cho Esther | CLO | sale | 4.48k | -$4.61M | S | +1.1% | 08/20 | 08/18 | |
| KROS | Newton Charles W. | DIR | sale10b5-1 | 551 | -$567k | S | +1.1% | 08/20 | 08/18 |
Keros Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Keros Therapeutics, Inc.?
Tanini Annita, Lerner Lorena Raquel, Cho Esther, Newton Charles W..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Tanini Annita reported a sale on Aug 18, 2026 valued at $1.25M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $101,135.63. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.